Program
Base Edited Natural Killer Cells NK510
Also written as “NK510” and “NK510 : allogeneic genetic modified NK”.
Its studies are mostly in Stomach Neoplasms · Lupus Erythematosus, Systemic · Osteosarcoma, led by Base Therapeutics (Shanghai).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Base Therapeutics (Shanghai) | 43 open or running | early phase 1since Oct 17, 2023 | Oct 17, 2023 | Jun 2027early phase 1 · NCT07166263 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2023First studies: 2 early phase 1 studiesFirst studyNCT06098898, NCT06117878
- Jul 16, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT07083349 · 4 enrolled · China
- Sep 3, 2025Early phase 1 study in Stomach NeoplasmsNCT07166263 · 15 planned · China
Ahead
- Jun 2027Primary completion: early phase 1 study in Stomach NeoplasmsNCT07166263
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07166263Stomach Neoplasms · China | Early 1 | Recruiting | Jun 2027 | 15 |
| NCT07083349Lupus Erythematosus, Systemic · China | Early 1 | Terminated | Apr 1, 2026 | 4 |
| NCT06117878Osteosarcoma · China | Early 1 | Recruiting | Sep 1, 2024 | 12 |
| NCT06098898Stomach Neoplasms · China | Early 1 | By invitation | Nov 1, 2024 | 9 |
How it is read
Names in the registry
- “NK510”, 5 entries
- “NK510 : allogeneic genetic modified NK”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 2 studies
- Lupus Erythematosus, Systemic, 1 study
- Osteosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.